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Abstract
Background: Postherpetic neuralgia (PHN) interferes with patients’ quality of life, and disturbed sleep is a prevalent
complaint. Pain-associated sleep interference in turn enhances pain and/or reduces pain tolerance. Therefore, reducing
sleep interference by pain, in addition to pain control, may improve patient care. To address this notion, we characterized
relationships among changes in pain intensity, sleep interference, and overall impression of improvement in PHN patients
treated with gastroretentive gabapentin (G-GR).
Methods: Patients with PHN (n = 556) received G-GR 1800 mg once-daily in two phase 3 and one phase 4 study.
Visual Analog Scale (VAS) and Brief Pain Inventory (BPI) were completed at baseline and the end of study. Patients’ Global
Impression of Change (PGIC) was completed at the end of study. Regression analyses examined relationships between
VAS, BPI sleep interference by pain, and PGIC.
Results: At the end of treatment, 53.7 and 63.2 % of patients reported a ≥30 % reduction in VAS and BPI pain-associated
sleep interference (BPISI) respectively; 46.3 % reported feeling “Much” or “Very Much” improved on the PGIC. There were
positive correlations between the percent reductions in VAS and BPISI; both correlated with PGIC improvements. Percent
changes in VAS and BPISI were significant (p < 0.0001 and p = 0.0082, respectively), and were independent predictors of
feeling “Much” or “Very Much” improved on the PGIC.
Conclusions: Reductions in pain intensity and in BPISI were correlated, and both also correlated with overall impression
of improvement for patients with PHN treated with G-GR. Both pain relief and improvement BPISI independently
predicted improvement in PGIC. For optimal patient care, clinicians should consider reducing the impact of pain
on quality of sleep as well as overall pain reduction.
Trial registration: ClinicalTrials.gov numbers, NCT00335933, NCT00636636, NCT01426230.
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Background
Postherpetic neuralgia (PHN) is a chronic neuropathic
pain syndrome resulting from nerve damage caused by
the varicella zoster virus that is reactivated during acute
herpes zoster (HZ, shingles) [1]. PHN, which occurs in
up to 20 % of HZ patients, can be debilitating and
interferes with patients’ physical function and their
quality of life [2–6]. Consistent with the tendency of
neuropathic pain to be worst during the night [7],
sleep disturbance is one of the most common com-
plaints among patients with PHN. Sleep disturbance
may in turn lead to additional comorbid conditions
such as anxiety or depression [5, 8–10], and some
studies suggest that shortened or disturbed sleep may
lead to reduced pain tolerance [11, 12]. Evidence sup-
ports a reciprocal relationship between pain and sleep
in which pain disturbs sleep, and poor sleep enhances
pain [6, 8, 13]. Thus, it is expected that improvement
in sleep quality, in addition to control of neuropathic
pain, may improve patients’ overall quality of life [14].
Although the beneficial effect of various formulations
of gabapentin [G-GR [15, 16], gabapentin enacarbil [17],
and an immediate-release gabapentin [18, 19] on the
quality of sleep has been described in several studies, the
relationship between changes in pain and sleep and how
they contribute to overall patient improvement is com-
plex, and are not well understood. A recent analysis of
integrated data from phase 3 and 4 studies of gastrore-
tentive gabapentin (G-GR) 1800 mg once-daily reported
widespread, networked, positive correlations among effi-
cacy endpoints, including among pain qualities on the
VAS and BPI, pain interference on the BPI, and overall
improvement on the PGIC [20]. In the current study, we
extend these findings by examining, at the individual pa-
tient level, the relationship between changes in pain inten-
sity and pain interference with sleep, and how changes in




Individual patient data from 566 PHN patients in two
double-blind, randomized, placebo-controlled phase 3
studies (NCT00335933 and NCT 00636636) and one
open-label, single-arm phase 4 study (NCT01426230)
were pooled in the analysis. Patient inclusion and exclu-
sion criteria of individual studies included in this analysis
have been described in detail elsewhere [21–23]. Briefly, in
the phase 3 studies, eligible patients were ≥18 years, with
neuropathic pain for ≥3 months or ≥6 months after the
healing of herpes zoster skin rash, and had an average
daily pain score of ≥4 based on an 11-point Likert scale
(where 0 = no pain and 10 = worst possible pain). In the
phase 4 study, patients were relatively unselected to best
reflect the real-world population, and included pa-
tients ≥18 years with active PHN, regardless of their
baseline pain scores. Only patients with valid baseline
efficacy measures and who received treatment with G-
GR 1800 mg once daily were included. Individual
study protocols were approved by appropriate institu-
tional review boards/ethics committees for each center
and were conducted in accordance with International
Conference on Harmonization (ICH) Good Clinical
Practice guidelines. Written informed consent was ob-
tained from each patient prior to enrollment.
Treatments
All three studies shared a similar G-GR treatment schedule:
a 2-week titration period, a stable dose treatment period
(8 weeks for phase 3, and 6 weeks for phase 4), and a
1-week dose tapering period. The 2-week titration
period used a set schedule: Day 1: 300 mg; Day 2:
600 mg; Days 3–6: 900 mg; Days 7–10: 1200 mg; Days
11–14: 1500 mg; Day 15: 1800 mg.
Efficacy evaluations
In the current analysis, pain intensity scores were from
the 100-mm VAS, which was used in all three studies. For
the phase 3 studies, VAS was a component of the Short-
Form-McGill Pain Questionnaire (SF-MPQ), completed
as a secondary efficacy variable. In the phase 4 study, VAS
was the primary efficacy variable for measurement of pain
intensity. Pain interference with sleep was evaluated using
the BPI, which was one of the secondary efficacy end-
points in both the phase 3 and phase4 studies. Pain-
associated BPI sleep interference (BPISI) was assessed on
an 11-point numeric rating scale (NRS) ranging from 0
(pain does not interfere with sleep) to 10 (pain completely
interferes with sleep). Overall improvements on the PGIC
were evaluated as secondary efficacy endpoints in phase 3
and phase 4 studies. The VAS and BPI were completed at
the end of the baseline week, at Week 2, and at the end of
the efficacy treatment period (Week 8 or 10) or early
termination. The PGIC was completed at the end of the
efficacy treatment period (Week 8 or 10) or early termin-
ation. For the integrated analysis, the end of the study was
defined as Week 10 for phase 3, and Week 8 for phase 4.
Statistical methods
Efficacy analyses were performed for all patients who
received ≥1 dose of study drug. Percent changes from
baseline to the end of the study in VAS pain intensity
and BPISI, and the proportion of patients categorized as
“Very Much Improved”, “Much Improved”, “Minimally
Improved”, “No Change”, “Minimally Worse”, “Much
Worse”, or “Very Much Worse” on the PGIC at the end
of the study were determined. Changes from baseline in
VAS and BPISI scores were estimated with an analysis of
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covariance (ANCOVA) model that included treatment,
study centers, and the baseline value as covariates. As
last observation carried forward (LOCF) was the pre-
determined method approved for all individual studies,
missing data were imputed by LOCF to follow approved
protocols. Exploratory analyses were designed to examine
relationships among treatment outcomes for patients with
potentially clinically significant responses to treatment
with G-GR. Therefore, “Very Much Improved” and “Much
Improved” responses on the PGIC were grouped together,
and “Minimally Improved”, “No Change”, “Minimally
Worse”, “Much Worse”, or “Very Much Worse” were
grouped into “Not Improved”. Furthermore, in accordance
with the published literature and the consensus sum-
mary statement produced by the Initiative on Methods,
Measurement, and Pain Assessment in Clinical Trials
(IMMPACT) [24–26], reductions of ≥30 % served as
determinants of clinically important reductions from
baseline in the VAS or BPISI scores. Relationships between
percent changes in various efficacy outcomes were ex-
amined using linear regression model ANOVA. Multi-
variable logistic regression analyses were performed to
evaluate percent changes in VAS and BPISI as predictive
factors for being “Much” or “Very Much” improved on
the PGIC. To measure the degree of linear dependence
between percent reductions in the VAS and BPISI scores,
the Pearson correlation coefficient (r) was determined.
Results
Patient characteristics
The integrated dataset from the phase 3 and 4 studies
included 546 patients in the efficacy population and 556





Mean (SD) 66.7 (12.9)
Median 69.0
Range 18–92
Age category, n (%)
< 55 years 89 (16.0)
55–64 years 109 (19.6)
65–74 years 195 (35.1)
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Baseline VAS category, n (%)
≤ 20 mm 15 (2.7)
> 20 mm 531 (95.5)
Baseline BPI Sleep Interference by Pain
Mean (SD) 5.1 (2.9)
Median 5
Range 0–10
























Fig. 1 Proportion of patients who reported ≥30 % reductions in the
VAS or BPI Sleep Interference by Pain scores, or who reported feeling
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Fig. 2 Percent reduction from baseline in the BPISI score by categories
of percent reduction from baseline in the VAS score
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patients in the safety population. Patient demographics
and baseline disease characteristics were similar between
studies (Table 1). The mean patient age was 66.7 years,
and the majority of patients were Caucasian (86.2 %)
and female (60.3 %). The mean baseline VAS score was
66.1 mm on the 100-mm scale. The mean baseline BPISI
score was 5.1 on the 0–10 NRS scale, and 9 % of pa-
tients had a baseline score of 0.
Correlation between pain relief and sleep interference by
pain improvement
At the end of G-GR treatment, 53.7 % of patients in the
efficacy population reported ≥30 % reduction in pain in-
tensity on the VAS, 63.2 % of patients reported ≥30 %
reduction in BPISI, and 46.3 % of patients reported feel-
ing “Much” or “Very Much” improved on the PGIC
(Fig. 1). A comparison of changes in VAS and BPISI
scores from baseline showed that a larger percent re-
duction from baseline in the VAS score was associated
with a larger percent reduction in the BPISI score at
the end of the study (Fig. 2). For patients with clinic-
ally significant reduction (defined as ≥30 % reduction
from baseline) in the VAS score, there was a linear
correlation between percent reductions in the VAS
and BPISI scores, (r = 0.28, p < 0.0001), whereas for
patients with <30 % reduction in the VAS score, there
was no linear correlation with BPISI (r = 0.0612, p =
0.3608; Table 2). Significantly more patients with
≥30 % reduction in the VAS score from baseline than
with <30 % reduction in the VAS score (72.0 vs.
39.5 % of patients, p < 0.0001) simultaneously reported
≥30 % reduction in the BPISI score (Table 3). Also,
among patients with ≥30 % reduction in the VAS score
from baseline, more simultaneously reported ≥30 %
reduction in the BPISI score than <30 % reductions in
BPISI score (72.0 vs. 19.1 % of patients, p < 0.0001).
Influence of pain relief and sleep improvement on overall
impression of improvement
Better overall improvement as assessed by the PGIC was
associated with larger percent reductions from baseline
in the VAS (Fig. 3a) and BPISI (Fig. 3b) scores. Significantly
more patients with ≥30 % reduction than with <30 %
reduction in the VAS score (70.2 vs. 17.9 % of patients,
p < 0.0001) were “Much” or “Very Much” improved on
the PGIC (Table 4). Furthermore, among patients with
≥30 % reduction in the VAS score, more were “Much”
or “Very Much” improved on the PGIC than not im-
proved (70.2 vs. 29.8 % of patients, p < 0.0001). In con-
trast, among patients with <30 % reduction in the VAS
score, more were not improved than “Much” or “Very
Much” improved on the PGIC (82.1 vs. 17.9 % of pa-
tients, p < 0.0001). The relationship between percent
reduction in the BPISI score and improvements on the
PGIC was similar, and more patients with ≥30 % reduc-
tion than with <30 % reduction in the BPISI score (57.8
vs. 26.9 % of patients, p < 0.0001) were simultaneously
“Much” or “Very Much” improved on the PGIC
(Table 5).
Additional exploratory analyses were done to evaluate
the influence of percent changes in the VAS and BPI
Interference scores on being “Much” or “Very Much”
improved on the PGIC. The probability of being “Much”
or “Very Much” improved on the PGIC increased with
greater percent reductions from baseline in the VAS
(Fig. 4a) and BPISI (Fig. 4b) scores, whereas baseline
values did not have a positive effect (Figs. 4c, d). Overall,
percent changes in the VAS score had a greater influence
on the probability of being “Much” or “Very Much”
improved on the PGIC than did percent changes in the
BPISI score (p < 0.0001 vs. p = 0.0063). Baseline VAS
values had a marginally significant (p = 0.0429) negative
effect, and baseline BPISI values did not have a signifi-
cant influence (p = 0.8458). Furthermore, percent
changes from baseline in VAS and BPISI scores were
Table 2 Linear Pearson correlation coefficient correlation




≥30 % reduction in VAS 267 0.2795 <0.0001
<30 % reduction in VAS 225 0.0612 0.3608
Table 3 Relationship between percent reduction from baseline in BPI sleep interference by pain and percent reduction in VAS
≥30 % reduction in VASa <30 % reduction in VASa Difference p-value
(n = 293) (n = 253) % (95 % CI)
≥30 % reduction in BPI Sleep Interference, n (%) 211 (72.0) 100 (39.5) 32.49 (24.57, 40.41) <0.0001
<30 % reduction in BPI Sleep Interference, n (%) 56 (19.1) 125 (49.4) −30.29 (−37.93, −22.66) <0.0001
Difference, % (95 % CI) 52.90 (46.07, 59.73) −9.88 (−18.50, −1.26) n/a n/a
p-value <0.0001 0.0253 n/a n/a
aMissing data were excluded; number of patients does not add up to 100 %; n/a, not applicable
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both significant predictive factors for being “Much” or
“Very Much” improved on the PGIC (Table 6). However,
compared with the BPISI, the percent change in VAS
had a larger regression coefficient (0.03 vs. 0.006) and
was of greater significance (p < 0.0001 vs. p = 0.0082).
Because adding the interaction between percent
changes in the VAS and BPISI scores to the regression
model showed no significance (p = 0.4808) for being
“Much” or “Very Much” improved on the PGIC
(Table 6), these variables acted as independent predict-
ive factors for overall improvement.
Discussion
The intensity of neuropathic pain tends to progress
throughout the day, being worst at night and signifi-
cantly impairing sleep [6, 7, 27]. Inadequate or poor-
quality sleep may in turn contribute to stress and other
negative consequences of living with pain, including re-
duced pain tolerance [6, 8, 10, 13]. In this analysis, we
investigated the correlation between G-GR-mediated
changes in BPISI, VAS pain scores, and PGIC scores at
the individual patient level.
In a prior analysis, positive correlations were observed
among VAS, overall BPI scores, pain interference on the
BPI, and PGIC, suggesting positive feedback loops in which
pain interferes with patient functioning, and poor function-
ing enhances pain [20]. Here we have extended the analysis
to evaluate the relationship with pain-associated sleep inter-
ference. As in our prior analysis, a 30 % reduction in pain
intensity was chosen as a cut-point for evaluating correla-
tions. In accordance with IMMPACT recommendations for
determining clinically important differences in pain inten-
sity reductions ≥30 % are considered “moderately import-
ant” improvements, whereas decreases of ≥50 % are
considered “substantial” improvements [26, 28]. Use of the
30 % cutoff was considered a conservative approach.
Not surprisingly, clear correlations were observed in
our analysis among pain reduction, pain-associated sleep
interference and PGIC. Consistent with the notion that
mechanisms underlying pain relief and sleep improvement
may be distinct, both VAS and BPISI were independent
predictors for patients’ reporting “Much” or “Very Much”
improvement on the PGIC. In addition, 39.5 % of PHN
patients with no clinically significant reduction in VAS still
had a clinically significant reduction in BPISI. As gabapen-
tin is known to improve sleep quality by increasing slow-
wave sleep in both normal adults (31) and in patients with
epilepsy (32), a direct effect on sleep may have contributed
to improvements in BPISI independent of pain reduction.
No correlations were observed between BPISI and VAS
for those with a ≤30 % change. This result may not be
surprising, since a < 30 % change in VAS is considered
minimally important; it is likely that any correlations,



















































































Fig. 3 Percent reduction from baseline in the VAS (a) and BPISI (b)
scores by categories of improvement on the PGIC
Table 4 Relationship between percent reduction from baseline in VAS and improvement on the PGIC
≥30 % reduction in VAS <30 % reduction in VAS Difference p-value
(n = 285) (n = 240) % (95 % CI)
“Much” or “Very Much” improved on PGIC, n (%) 200 (70.2) 43 (17.9) 52.26 (45.06, 59.45) <0.0001
Not improved on PGICa, n (%) 85 (29.8) 197 (82.1) −52.26 (−59.45, −45.06) <0.0001
Difference, % (95 % CI) 40.35 (32.84, 47.86) −64.17 (−71.03, −57.31) n/a n/a
p-value <0.0001 <0.0001 n/a n/a
aIncludes patients from other PGIC categories: Minimally Improved, No Change, Minimally Worse, Much Worse, Very Much Worse; n/a, not applicable
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It is important to note that approximately 22 % of pa-
tients did not report clinically significant reductions in
pain or BPISI but still reported feeling “Much” or “Very
Much” improved on the PGIC at the end of treatment.
These results suggest a complex relationship among
patient-reported outcomes and that changes in other effi-
cacy measures, such as mood, opioid usage, and return to
work may also play a role. An analysis of pain reduction,
pain interference with sleep, and PGIC in patients treated
with placebo may also be of interest. In this study, since the
phase 4 study was a real-world, open label study with no
placebo control group, a rigorous analysis was not possible.
Our results are consistent with a study of pregaba-
lin in patients with diabetic peripheral neuropathy
(DPN) or PHN that showed similar correlations
between pain relief, sleep improvement, and
improvements in quality of life, and these improve-
ments were not solely mediated via control of pain or
sleep disturbance [14]. Interestingly, a different
pregabalin study in patients with neuropathic pain
of any origin reported that improvement in sleep
was a better predictor than a reduction in pain inten-
sity of improvements in health-related quality of life
[29].
Table 5 Relationship between percent reduction from baseline in BPI Sleep Interference by Pain and improvement on the PGIC
≥30 % reduction in BPI Sleep Interference <30 % reduction in BPI Sleep Interference Difference p-value
(n = 301) (n = 171) % (95 % CI)
“Much” or “Very Much” improved
on PGIC, n (%)
174 (57.8) 46 (26.9) 30.91 (22.23, 39.58) <0.0001
Not improved on PGICa, n (%) 127 (42.2) 125 (73.1) −30.91 (−39.58, −22.23) <0.0001
Difference, % (95 % CI) 15.61 (7.72, 23.50) −46.29 (−55.60, −36.80) n/a n/a
p-value 0.0001 <0.0001 n/a n/a
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Fig. 4 Influence of the VAS and BPI Sleep Interference by Pain scores on the probability to be “Much” or “Very Much” improved on the PGIC. Probabilities
to be “Much” or “Very Much” improved on the PGIC were determined by multiple logistic regression analyses for percent changes from baseline in the
VAS score (a) and BPI Sleep Interference by Pain score (b), and for baseline VAS (c) and BPI Sleep Interference by Pain (d) scores
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Conclusions
For the majority of patients with PHN and treated with
G-GR in these clinical trials, clinically significant reduc-
tions in pain intensity and pain-associated sleep interfer-
ence were correlated with, and independently predicted,
feeling “Much” or “Very Much” improved at the end of
the G-GR treatment. For optimal patient care, clinicians
should consider reducing the impact of pain on quality
of sleep as well as overall pain reduction.
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